Image

Ocular Therapeutix has obtained approval from the US Food and Drug Administration (FDA) for its ReSure sealant, indicated for prevention of postoperative fluid egress from incisions with a demonstrated wound leak following cataract surgery.

Approval allows Ocular Therapeutix to market its ReSure sealant, a polyethylene glycol (PEG)-based hydrogel, in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Ocular Therapeutix claims that the ReSure sealant is the first and only sealant that is FDA-approved for ophthalmic use.

ReSure sealant kit includes two liquid solutions that are mixed together just before the use. The kit also includes a foam-tipped applicator used for applying the mixture directly to the incision.

The sealant is applied as a liquid and gels in situ on the ocular surface. Within 20 seconds of applying the liquid to eye tissue, a gel forms on the eye and seals the incision.

See Also:

"This study demonstrated superiority over sutures by successfully preventing wound leaks in 95.9% of cases, compared with sutures in only 65.9% of cases."

The gel gradually breaks down over the course of seven days and is cleared from the body by the eye’s natural processes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Ocular Therapeutix has evaluated the ReSure sealant in a randomised, multicentre clinical trial for prevention of fluid egress in clear corneal incisions against sutures. This study demonstrated superiority over sutures by successfully preventing wound leaks in 95.9% of cases, compared with sutures in only 65.9% of cases.

In addition, the ReSure sealant demonstrated significantly fewer device-related adverse events than the control group.

Ocular Therapeutix president and CEO Dr Amar Sawhney: "We expect this novel product will enable surgeons to optimise post-operative care of their patients, and look forward to a successful launch in the United States."

Image: Cataract surgery is the most commonly performed surgery in the US. Photo: courtesy of EyeMD.